dimethyl fumarate neuraxpharm
laboratorios lesvi s.l. - dimethyl fumarát - roztroušená skleróza, relaps-remitentní - imunosupresiva - dimethyl fumarate neuraxpharma is indicated for the treatment of adult patients with relapsing remitting multiple sclerosis.
adele 0,15mg/0,03mg tableta
heaton k.s., praha array - 8386 desogestrel; 578 ethinylestradiol - tableta - 0,15mg/0,03mg - desogestrel a ethinylestradiol
natalya 0,15mg/0,02mg tableta
heaton k.s., praha array - 8386 desogestrel; 578 ethinylestradiol - tableta - 0,15mg/0,02mg - desogestrel a ethinylestradiol
vaniqa
almirall, s.a. - eflornithin - hirsutismus - ostatní dermatologické přípravky - léčba hirsutismu obličeje u žen.
birgi 0,060mg/0,015mg potahovaná tableta
aristo pharma gmbh, berlin array - 8280 gestoden; 578 ethinylestradiol - potahovaná tableta - 0,060mg/0,015mg - gestoden a ethinylestradiol
gracial tableta
aspen pharma trading limited, dublin array - 8386 desogestrel; 578 ethinylestradiol; 8386 desogestrel; 578 ethinylestradiol - tableta - desogestrel a ethinylestradiol
marvelon 0,15mg/0,03mg tableta
n.v. organon, oss array - 8386 desogestrel; 578 ethinylestradiol - tableta - 0,15mg/0,03mg - desogestrel a ethinylestradiol
mercilon 0,15mg/0,02mg tableta
n.v. organon, oss array - 8386 desogestrel; 578 ethinylestradiol - tableta - 0,15mg/0,02mg - desogestrel a ethinylestradiol
nelya 0,06mg/0,015mg potahovaná tableta
heaton k.s., praha array - 8280 gestoden; 578 ethinylestradiol - potahovaná tableta - 0,06mg/0,015mg - gestoden a ethinylestradiol
invokana
janssen-cilag international nv - kanagliflozin - diabetes mellitus, typ 2 - léky užívané při diabetu - invokana is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise:as monotherapy when metformin is considered inappropriate due to intolerance or contraindicationsin addition to other medicinal products for the treatment of diabetes. for study results with respect to combination of therapies, effects on glycaemic control, cardiovascular and renal events, and the populations studied, see sections 4. 4, 4. 5 a 5.